Rare diseases
Investigational molecules
Locations
Switching to Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults with HIV-1: A Phase 3 Randomized Study
FranceSwitching to lenacapavir-based drug combination vs cabotegravir-based drug combination in virologically suppressed adults with HIV-1
FranceStudy of Bictegravir and Lenacapavir for Children and Adolescents with HIV-1
ItalySafety and efficacy of GS-3242 drug combination compared with standard drug combination in treatment‑naive adults with HIV‑1
GermanyStudy on Lenacapavir for HIV Prevention in Individuals at Risk of HIV Infection
FranceStudy Comparing Weekly Islatravir/Lenacapavir Regimen to Standard Care in HIV Patients with Controlled Viral Load
GermanyStudy to Compare Weekly Islatravir/Lenacapavir with Bictegravir/Emtricitabine/Tenofovir in People with HIV-1 Who Are Virologically Suppressed
FranceStudy on Long-Acting Cabotegravir and Lenacapavir for HIV Patients: Evaluating Dual Antiretroviral Therapy
FranceStudy Comparing Bictegravir/Lenacapavir to Current Therapy in People with HIV-1 Who Are Successfully Treated
FranceStudy Comparing Bictegravir and Lenacapavir to Current Treatment in Patients with HIV-1 on Complex Regimens
FranceTell us about your condition – we search every trial in Europe and connect you with the right site.
